



**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Disease, Disability, and Injury Prevention and Control Special  
Emphasis Panel (SEP)- RFA-PS23-001, Increasing PrEP Use Among  
Disproportionately Affected Populations in the United States and  
RFA-PS23-003, Exploring Preferences for Long-Acting  
Antiretroviral Therapies (LA-ART) in a Community-Based Sample of  
Priority Populations Living with HIV Who are Disproportionately  
Affected; Amended Notice of Meeting**

Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)- *RFA-PS23-001, Increasing PrEP Use Among Disproportionately Affected Populations in the United States and RFA-PS23-003, Exploring Preferences for Long-Acting Antiretroviral Therapies (LA-ART) in a Community-Based Sample of Priority Populations Living with HIV Who are Disproportionately Affected*, May 11-12, 2023, 10 a.m. - 5 p.m., EDT, Teleconference, Centers for Disease Control and Prevention, Room 1077, 8 Corporate Blvd, Atlanta, GA 30329, in the original FRN. The meeting was published in the **Federal Register** on February 13, 2023, Volume 88, Number 29, page/s/ 9288-9289.

The meeting is being amended to change the title of RFA-PS23-001, Increasing PrEP Use Among Disproportionately Affected Populations in the United States to RFA-PS23-001, Increasing PrEP Use Among Black Cisgender Women in the United States (HerPrEP)

and to remove RFA-PS23-003, Exploring Preferences for Long-Acting Antiretroviral Therapies (LA-ART) in a Community-Based Sample of Priority Populations Living with HIV Who are Disproportionately Affected and replace with RFA-PS23-005, Expanding Rapid Initiation of Antiretroviral Therapy in Non-traditional Settings: Emergency Department. The date of the teleconference will also change and should read as follows:

Date: May 24-25, 2023

Place: Teleconference, Centers for Disease Control and Prevention, Room 1077, 8 Corporate Blvd, Atlanta, GA 30329.

The meeting is closed to the public.

**FOR FURTHER INFORMATION CONTACT:** Gregory Anderson, M.S., M.P.H., Scientific Review Officer, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC, 1600 Clifton Road, N.E., Mailstop US8-1, Atlanta, Georgia 30329, Telephone: (404) 718-8833, Email: *GAnderson@cdc.gov*.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign *Federal Register* notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit,  
Office of the Chief Operating Officer,*

*Centers for Disease Control and Prevention.*

[FR Doc. 2023-04697 Filed: 3/7/2023 8:45 am; Publication Date: 3/8/2023]